"Zycords" – Patent GRANTED by EPO!
Concenter Biopharma is proud to announce another acceptance of the Patent covering the Second Generation of the novel anti-diabetic drug candidate – the “Zycords”.
The patent was recently granted by the European Patent Office and was validated in major European countries.
The “Zycord” compounds work through the analogous mechanisms (to the Zygosid-50 drug) and are expected to demonstrate high therapeutic potential. The investigation of their safety and efficacy will begin later this year.
The priority patent of the “Zycord” family is 12/2014 and it is being examined in numerous jurisdictions worldwide. The Claims of this Patent protect the COMPOSITION OF MATTER of the Zycords - the novel family of compounds, defined as a platform of drugs, and include their use in medicine in several modes of administration.
